[go: up one dir, main page]

WO2009100441A3 - Depot formulations - Google Patents

Depot formulations Download PDF

Info

Publication number
WO2009100441A3
WO2009100441A3 PCT/US2009/033574 US2009033574W WO2009100441A3 WO 2009100441 A3 WO2009100441 A3 WO 2009100441A3 US 2009033574 W US2009033574 W US 2009033574W WO 2009100441 A3 WO2009100441 A3 WO 2009100441A3
Authority
WO
WIPO (PCT)
Prior art keywords
depot formulations
active agent
alpha
release
directed
Prior art date
Application number
PCT/US2009/033574
Other languages
French (fr)
Other versions
WO2009100441A2 (en
Inventor
Laman Alani
Shook Chin
Amy Ding
Original Assignee
Impax Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impax Laboratories, Inc. filed Critical Impax Laboratories, Inc.
Publication of WO2009100441A2 publication Critical patent/WO2009100441A2/en
Publication of WO2009100441A3 publication Critical patent/WO2009100441A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

In certain embodiments the present invention is directed to a pharmaceutical depot formulation comprising an active agent, such as an alpha-2-adrenergic agonist, that can release an effective amount of the active agent over an extended period of time.
PCT/US2009/033574 2008-02-08 2009-02-09 Depot formulations WO2009100441A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2733308P 2008-02-08 2008-02-08
US61/027,333 2008-02-08

Publications (2)

Publication Number Publication Date
WO2009100441A2 WO2009100441A2 (en) 2009-08-13
WO2009100441A3 true WO2009100441A3 (en) 2010-01-14

Family

ID=40952737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/033574 WO2009100441A2 (en) 2008-02-08 2009-02-09 Depot formulations

Country Status (1)

Country Link
WO (1) WO2009100441A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8889173B2 (en) 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8883768B2 (en) 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8946277B2 (en) 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US8822546B2 (en) 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
WO2011133370A1 (en) * 2010-04-23 2011-10-27 Medtronic, Inc. Shelf stable pharmaceutical depot
WO2012075451A2 (en) * 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Clonidine and gaba compounds in a biodegradable polymer carrier
US9005634B2 (en) 2011-04-13 2015-04-14 Medtronic, Inc. Shelf stable pharmaceutical depot
US9511018B2 (en) * 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
CN107428697A (en) * 2015-01-06 2017-12-01 塞尔利克斯生物私人有限公司 For treating the composition and method of inflammation and pain
WO2018136787A1 (en) * 2017-01-20 2018-07-26 Warsaw Orthopedic, Inc. Anesthetic compositions and methods comprising imidazoline compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US20070232529A1 (en) * 2000-08-22 2007-10-04 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20070243228A1 (en) * 2006-04-13 2007-10-18 Mckay William F Drug depot implant designs and methods of implantation
US20070251530A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Screening candidates for implantable infusion devices

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070232529A1 (en) * 2000-08-22 2007-10-04 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US20070243228A1 (en) * 2006-04-13 2007-10-18 Mckay William F Drug depot implant designs and methods of implantation
US20070251530A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Screening candidates for implantable infusion devices

Also Published As

Publication number Publication date
WO2009100441A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
WO2009100441A3 (en) Depot formulations
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
WO2008116135A3 (en) Topical formulations having enhanced bioavailability
WO2008048963A3 (en) Natural compositions for killing parasites on a companion animal
WO2009007328A3 (en) Use of homo- and copolymers for stabilizing active ingredient formulations
EP2039366A4 (en) Composition containing peptide as the active ingredient
HK1216319A1 (en) Anhydrous hydrogel composition
PL2081547T3 (en) Galenic form for the trans-mucosal delivery of active ingredients
WO2007100776A3 (en) Antimicrobial compositions and methods for locking catheters
WO2011051354A3 (en) Transdermal pharmaceutical compositions comprising active agents
PL1981915T3 (en) Compositions of active ingredients
WO2008009379A3 (en) Active ingredient combinations having insecticide and acaricide properties
WO2009091576A3 (en) Parenteral formulations of dopamine agonists
WO2009074735A3 (en) Use of a novel natural agent in cosmetic compositions
WO2010021607A3 (en) Pharmaceutical formulation
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
WO2013175221A3 (en) Composition
WO2008039472A3 (en) Stabilizing compositions for antibiotics and methods of use
MY159492A (en) Solid pharmaceutical formulation with delayed release
WO2007095258A3 (en) Rhamnolipid compositions and related methods of use
WO2010079047A3 (en) Octreotide depot formulation with constantly high exposure levels
WO2011039444A3 (en) Composition, use, and preservation method
WO2011107713A3 (en) Novel agent for improving the deposition of oil on hair
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09708208

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09708208

Country of ref document: EP

Kind code of ref document: A2